Development and Validation of Ferroptosis-Related lncRNAs as Prognosis and Diagnosis Biomarkers for Breast Cancer

Breast cancer (BC) is one of the most common malignancies affecting women. Ferroptosis is a novel cancer treatment option. The present study is aimed to identify suitable ferroptosis-related lncRNAs to predict and diagnose BC. Differential expression and Cox regression analyses were used to screen s...

Full description

Saved in:
Bibliographic Details
Published in:BioMed research international 2022-10, Vol.2022, p.1-14
Main Authors: Yao, Zhi-Yong, Xing, Chaoqun, Cai, Shanshan, Xing, Xiao-Liang
Format: Article
Language:English
Subjects:
Age
Apoptosis
Biomarkers
Breast cancer
Cancer therapies
Chemotherapy
Development and progression
Diagnosis
Ferroptosis
Gene expression
Genetic aspects
Genetic markers
Health aspects
Identification and classification
Medical prognosis
Non-coding RNA
Physiological aspects
Regression analysis
Risk assessment
RNA
Software
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Breast cancer (BC) is one of the most common malignancies affecting women. Ferroptosis is a novel cancer treatment option. The present study is aimed to identify suitable ferroptosis-related lncRNAs to predict and diagnose BC. Differential expression and Cox regression analyses were used to screen suitable prognostic biomarkers and construct a suitable risk model. We identified four ferroptosis-related differentially expressed lncRNAs (FR-DELs) (LINC01152, AC004585.1, MAPT-IT1, and AC026401.3), which were independently correlated with the overall survival of BC patients. The area under the curve value of the prognostic model using those four biomarkers was over 0.60 in all three groups. The sensitivity and specificity of the diagnostic model using those four biomarkers were 86.89% and 86.73%, respectively. Our present study indicated that these four FR-DELs (LINC01152, AC004585.1, MAPT-IT1, and AC026401.3) could be prognostic biomarkers for BC, although clinical validation studies are required.
ISSN:2314-6133
2314-6141
DOI:10.1155/2022/2390764